Business context and reporting period
Entity mismatch: The request identifies SAB Biotherapeutics, Inc., but the supplied filing is Big Cypress Acquisition Corp.’s Form 10-Q for the quarter ended March 31, 2021. The summary below covers the filing provided.
Big Cypress was a blank-check company seeking a business combination and had not begun operating activities or generated operating revenue. It completed its IPO on January 14, 2021, placing $116.15 million in a trust account. Its business-combination period was 15 months after the IPO, potentially extendable to 21 months.
Financial results and liquidity
| Metric | Three months ended March 31, 2021 / period-end |
|---|---|
| Operating revenue | None |
| Operating costs and operating loss | $111,612 |
| Net income | $2,973,220, including a $3,442,287 noncash gain from the change in fair value of warrant liabilities |
| Interest income | $2,419 |
| Basic and diluted net income per share | $0.84 |
| Cash outside the trust | $858,055 |
| Trust-account marketable securities | $116,152,419 |
| Total assets | $117,273,057 |
| Total liabilities | $7,883,396, including $4,220,500 of deferred underwriting fees and $3,582,896 of warrant liabilities |
| Common stock subject to possible redemption | $104,389,656 |
| Stockholders’ equity | $5,000,005 |
| Cash flows | $363,159 used in operations; $116,150,000 used for trust-account investments; $117,286,378 provided by financing activities |
The filing reports no long-term debt and no outstanding working-capital loans at quarter-end. The deferred underwriting fee is payable from the trust only if a business combination is completed. No operating margins are meaningful because the company had no revenue.
Changes, unusual items, outlook and risks
- The company restated its previously issued January 14, 2021 balance sheet after changing its accounting for public and private warrants. The warrants are now classified as derivative liabilities and remeasured at fair value each reporting period. The quarter’s reported net income includes the resulting noncash gain.
- Management reported a material weakness in internal control over financial reporting related to warrant accounting and concluded that disclosure controls were ineffective. It planned to strengthen review, documentation and accounting procedures during 2021, but gave no assurance that remediation would be successful.
- Management expected to use trust funds for a business combination and outside-trust cash for target searches and transaction expenses. It said additional funding might be needed if costs exceed estimates, redemptions are substantial, or post-combination cash is insufficient. If the company failed to complete a combination within the permitted period, it would redeem public shares and liquidate.
- The filing identifies COVID-19 as a potential risk to the company’s financial position, operations and target search, but says the specific impact was not determinable. It also notes that sponsor indemnification of certain trust claims may be difficult to collect because the sponsor’s resources were not verified.
- Warrant fair-value changes may create material earnings fluctuations and, in management’s view, could affect the stock price or make a business combination more difficult. The trust was invested in Treasury-focused money-market funds; management reported no material market or interest-rate exposure.
- There were no legal proceedings reported. The company incurred a $10,000 monthly administrative-services fee to a sponsor affiliate, beginning January 14, 2021.
Important facts for investors to verify
- Confirm the filing’s registrant: this is Big Cypress Acquisition Corp., not SAB Biotherapeutics, Inc.
- Review the warrant-liability restatement, valuation assumptions and future fair-value effects; reported income is substantially affected by a noncash warrant gain.
- Assess the material weakness, the remediation plan and whether controls were subsequently improved.
- Verify the business-combination deadline, any extension, transaction status, redemption levels and the amount of cash available outside the trust.
- Reconcile apparent inconsistencies within the supplied filing text: common shares are stated as both 4,456,591 and 4,465,591; financing cash flow differs between the cash-flow statement and MD&A; and offering-cost totals also vary across sections. The filing text does not provide a clear reconciliation.